Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDV Insulin Lispro vs Standard Lispro in T1DM CSII
NCT03156361Phase 2Completed
- Sponsor
- Diasome Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of insulin lispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Diasome Pharmaceuticals. Primary endpoint: Glucose area under the curve at 21 days. Started May 2017; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03156361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156361.